Phaseline

Companies › Kaken Pharmaceutical

Kaken Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KP-001–Phase 3Venous MalformationsFeb 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07285005KP-001Phase 3Venous MalformationsOtherFeb 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Acer Therapeutics Shanghai Haiyan Pharmaceutical Technology Spine BioPharma Vertanical NTC srl

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.